Company: INDP
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001641172-25-006429
Chunk: 5

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 5
---
 the Securities and Exchange Commission (“SEC”) on March 13, 2025 (the “2024 Annual Report”) will be released on or about April 28, 2025 to our stockholders on the Record Date.

In this proxy statement, “Indaptus”, “Company”, “we”, “us”, and “our” refer to Indaptus Therapeutics, Inc. (formerly Intec Parent, Inc.) and, where appropriate, its consolidated subsidiaries, Intec Pharma Ltd. and Decoy Biosystems, Inc. References to “Intec Parent” refer to Intec Parent, Inc., the successor of Intec Pharma Ltd. following the domestication merger (the “Domestication Merger”) with Intec Parent, references to “Intec Israel” refer to Intec Pharma Ltd., the predecessor of Indaptus prior to the Domestication Merger, and references to “Decoy” refer to Decoy Biosystems, Inc., the entity acquired by Indaptus in connection with the merger with Decoy (the “Merger”).

<div align='center'>IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE

STOCKHOLDER MEETING TO BE HELD ON TUESDAY, JUNE 10, 2025

This Proxy Statement and our 2024 Annual Report to Stockholders are available at

http://www.proxyvote.com/</div>

Proposals

At the Annual Meeting, our stockholders will be asked:

| ● 
 ● | To                                                                                                                                      
 elect Mark J. Gilbert, M.D., Hila Karah, and Robert E. Martell, M.D., Ph.D as Class I directors, to serve until the 2028 Annual Meeting 
 of Stockholders, and until their respective successors have been duly elected and qualified (the “Director Election Proposal”);         
 To                                                                                                                                      
 ratify the appointment of Haskell & White LLP as our independent registered public accounting firm for the fiscal year ending           
 December 31, 2025 (the “Auditor Reappointment Proposal”);                                                                               |
|:--|:----------------------------------------------------------------------------------------------------------------------------------------|
| ● | To                                                                                                                                      
 approve, on an advisory basis, the compensation paid to our named executive officers (the “Executive Compensation Proposal”);           |

| 2 |

| ● | To                                                                                                                               
 approve an amendment to our Amended and Restated Certificate of Incorporation, as amended                                        
 (the “Restated Certificate”), in the form set forth on Appendix A attached                                                       
 to this Proxy